Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Onglyza earns European approval for Type 2 Diabetes treatment
The approval is backed by Phase 3b 24-week data that demonstrated the efficacy of Onglyza in reducing blood sugar levels in type 2 diabetes as compared to placebo.
The approval is backed by Phase 3b 24-week data that demonstrated the efficacy of Onglyza in reducing blood sugar levels in type 2 diabetes as compared to placebo.
Pollinex Quattro Complete (MATA MPL) is a four injection therapeutic vaccine, used to treat allergic conditions which provides relief in three weeks after treatment. The company has also
The software solution is believed to provide EHR documentation and patient charting solution. Electronic documentation and document imaging for all elements of the patient encounter will be offered
MHC is a large cluster of genes found on the short arm of chromosome 6 including 150 expressing genes which progresses diseases like AIDs, arteriosclerosis, cancers, diabetes and
According to the company, its products are natural with 1:1 balance of fructose and glucose making them optimum for liver, brain and muscle function, modbee.com reported. The 1:1
NurAiD II comprises a blend of nine medicinal Chinese herbal extracts. The product is used to stimulate neuroplasticity of healthy tissues, thereby aiding in the recovery of both
Under the agreement, GVK BIO will be responsible for the target validation, lead identification and lead optimization of small molecules in selected therapeutic areas including cardiovascular, central nervous
The study published as a research article, ‘Activity-Based Chemical Proteomics Accelerates Inhibitor Development for Deubiquitylating Enzymes’ investigated the details of a novel proteomics based method in detecting inhibition
BOL-303259- X, a NO-donating prostaglandin F2-alpha analog, helps lower intraocular pressure (IOP) through a dual mechanism of action. The study will evaluate the most effective dose of BOL-303259-X,
The ten-year collaboration agreement will focus on translational research for innovative therapies for Alzheimer’s and Parkinson’s diseases. The Cambridge-Elan Centre will discover novel compounds capable of altering the